An update on the diagnostic biomarkers for asthma
- PMID: 34041141
- PMCID: PMC8140254
- DOI: 10.4103/jfmpc.jfmpc_2037_20
An update on the diagnostic biomarkers for asthma
Abstract
Asthma is a respiratory disorder accounts for ~339 million cases per annum. The initial diagnosis of asthma relies on the symptomatic identification of characters, such as wheeze, shortness of breath, chest tightness, and cough. The presence of two or more of these symptoms may be considered as indicative of asthma. The asthma-diagnostic also involves spirometry test before and after inhaling a bronchodilator like albuterol. Because asthma pathophysiology involves participation of immune system, the cytokines play an important role. The review discusses various molecules that are or may be used as biomarkers for the asthma diagnosis.
Keywords: Asthma; IL-17; chronic; interleukins; respiratory.
Copyright: © 2021 Journal of Family Medicine and Primary Care.
Conflict of interest statement
There are no conflicts of interest.
References
-
- GINA, Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019
-
- M Kenawy E, El-Hafeez A, Mohamed AE-G, MA Naeem M. Interleukin (il)-17 as a biomarker in assessment of bronchial asthma severity. Al-Azhar Med J. 2017;46:443–54.
-
- GlobalAsthmaReport. 2018. Available from: http://www.globalasthmareport.org/Global20Asthma20Report202018.pdf .
-
- WHO. 2019. Available from: https://www.who.int/newsroom/q-a-detail/asthma .
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources